We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Sanofi | NASDAQ:SNY | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.80 | 1.63% | 50.03 | 50.03 | 50.20 | 50.37 | 48.85 | 49.17 | 1,363,472 | 00:58:44 |
By Joseph Walker
Regeneron Pharmaceuticals Inc. and Sanofi S.A. said they will charge $37,000 annually in the U.S. for their newly approved eczema drug, a price the companies said they reached after months of negotiations with pharmacy benefit managers.
The Food and Drug Administration approved the drug, called Dupixent, for U.S. sale on Tuesday.
Through their negotiations, the companies said they aimed to set a price the pharmacy benefit managers, or PBMs, would find acceptable. PBMs administer prescription drug benefits for employers and insurers.
In exchange, the companies sought, and in some cases received, assurances that the PBMs wouldn't implement coverage restrictions that could prevent patients from getting the drug, Regeneron CEO Leonard Schleifer said in an interview.
Dupixent will be one of the most closely watched drug launches this year, with analysts projecting it could reach $3.13 billion in global annual sales in 2020 if it gains favorable insurance coverage, according to analysts polled by FactSet.
--Denise Roland contributed to this article.
(END) Dow Jones Newswires
March 28, 2017 12:11 ET (16:11 GMT)
Copyright (c) 2017 Dow Jones & Company, Inc.
1 Year Sanofi Chart |
1 Month Sanofi Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions